Psoriatic Arthritis – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Psoriatic Arthritis – Pipeline Review, H2 2017’, provides an overview of the Psoriatic Arthritis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Psoriatic Arthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Psoriatic Arthritis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Psoriatic Arthritis

The report reviews pipeline therapeutics for Psoriatic Arthritis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Psoriatic Arthritis therapeutics and enlists all their major and minor projects

The report assesses Psoriatic Arthritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Psoriatic Arthritis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Psoriatic Arthritis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Psoriatic Arthritis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3SBio Inc

AbbVie Inc

AbGenomics International Inc

Aclaris Therapeutics Inc

Adello Biologics LLC

Allergan Plc

Alteogen Inc

Amgen Inc

Biocon Ltd

Bionovis SA

Coherus BioSciences Inc

Eli Lilly and Co

Formycon AG

Forward Pharma AS

Fresenius SE & Co KGaA

Galapagos NV

Genor BioPharma Co Ltd

Immunwork Inc

Innovent Biologics Inc

Johnson & Johnson

KPI Therapeutics Inc

Morphotek Inc

Mycenax Biotech Inc

Nichi-Iko Pharmaceutical Co Ltd

Novo Nordisk AS

Nuevolution AB

Oncobiologics Inc

Pfizer Inc

Reliance Life Sciences Pvt Ltd

Rigel Pharmaceuticals Inc

Sandoz International GmbH

Sun Pharma Advanced Research Company Ltd

SynAct Pharma AB

UCB SA

Xbrane Biopharma AB

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 7

Global Markets Direct Report Coverage 7

Psoriatic Arthritis - Overview 8

Psoriatic Arthritis - Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Products under Development by Companies 14

Psoriatic Arthritis - Therapeutics Assessment 18

Assessment by Target 18

Assessment by Mechanism of Action 20

Assessment by Route of Administration 22

Assessment by Molecule Type 24

Psoriatic Arthritis - Companies Involved in Therapeutics Development 26

3SBio Inc 26

AbbVie Inc 26

AbGenomics International Inc 27

Aclaris Therapeutics Inc 27

Adello Biologics LLC 27

Allergan Plc 28

Alteogen Inc 28

Amgen Inc 29

Biocon Ltd 29

Bionovis SA 30

Coherus BioSciences Inc 30

Eli Lilly and Co 31

Formycon AG 31

Forward Pharma AS 32

Fresenius SE & Co KGaA 32

Galapagos NV 33

Genor BioPharma Co Ltd 33

Immunwork Inc 33

Innovent Biologics Inc 34

Johnson & Johnson 34

KPI Therapeutics Inc 35

Morphotek Inc 35

Mycenax Biotech Inc 35

Nichi-Iko Pharmaceutical Co Ltd 36

Novo Nordisk AS 36

Nuevolution AB 37

Oncobiologics Inc 37

Pfizer Inc 38

Reliance Life Sciences Pvt Ltd 38

Rigel Pharmaceuticals Inc 39

Sandoz International GmbH 39

Sun Pharma Advanced Research Company Ltd 40

SynAct Pharma AB 40

UCB SA 41

Xbrane Biopharma AB 41

Psoriatic Arthritis - Drug Profiles 42

AbGn-168H - Drug Profile 42

adalimumab biosimilar - Drug Profile 45

adalimumab biosimilar - Drug Profile 46

adalimumab biosimilar - Drug Profile 47

adalimumab biosimilar - Drug Profile 48

adalimumab biosimilar - Drug Profile 49

adalimumab biosimilar - Drug Profile 50

adalimumab biosimilar - Drug Profile 53

adalimumab biosimilar - Drug Profile 54

adalimumab biosimilar - Drug Profile 55

adalimumab biosimilar - Drug Profile 57

adalimumab biosimilar - Drug Profile 58

adalimumab biosimilar - Drug Profile 59

adalimumab biosimilar - Drug Profile 60

AGR-131 - Drug Profile 61

AK-101 - Drug Profile 62

AK-111 - Drug Profile 63

AP-1189 - Drug Profile 64

apremilast - Drug Profile 66

ATI-450 - Drug Profile 67

baricitinib - Drug Profile 68

bimekizumab - Drug Profile 80

certolizumab pegol - Drug Profile 83

certolizumab pegol biosimilar - Drug Profile 97

clazakizumab - Drug Profile 98

dalazatide - Drug Profile 102

dimethyl fumarate - Drug Profile 107

DNX-114 - Drug Profile 109

DNX-514 - Drug Profile 110

etanercept - Drug Profile 111

etanercept biosimilar - Drug Profile 113

etanercept biosimilar - Drug Profile 115

etanercept biosimilar - Drug Profile 116

etanercept biosimilar - Drug Profile 117

etanercept biosimilar - Drug Profile 118

etanercept biosimilar - Drug Profile 119

etanercept biosimilar - Drug Profile 122

etanercept biosimilar - Drug Profile 123

filgotinib - Drug Profile 124

golimumab biosimilar - Drug Profile 137

golimumab biosimilar - Drug Profile 138

GSK-3050002 - Drug Profile 139

guselkumab - Drug Profile 141

HEISCO-III-002 - Drug Profile 149

infliximab biosimilar - Drug Profile 150

infliximab biosimilar - Drug Profile 152

infliximab biosimilar - Drug Profile 153

infliximab biosimilar - Drug Profile 156

infliximab biosimilar - Drug Profile 157

infliximab biosimilar - Drug Profile 158

INV-17 - Drug Profile 159

ixekizumab - Drug Profile 160

liraglutide - Drug Profile 169

risankizumab - Drug Profile 179

Small Molecule to Antagonize ROR-Gamma for Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis - Drug Profile 184

Small Molecule to Inhibit IRAK1/4 for Arthritis and Psoriasis - Drug Profile 185

Small Molecules to Antagonize RORgamma for Rheumatoid Arthritis, Inflammatory Bowel Disease, Dermatology and Psoriatic Arthritis - Drug Profile 186

TE-2122 - Drug Profile 187

TE-2158 - Drug Profile 188

tildrakizumab - Drug Profile 189

tofacitinib citrate - Drug Profile 192

upadacitinib tartrate - Drug Profile 210

ustekinumab biosimilar - Drug Profile 216

ustekinumab biosimilar - Drug Profile 217

ustekinumab biosimilar - Drug Profile 218

VTP-43742 - Drug Profile 219

Psoriatic Arthritis - Dormant Projects 222

Psoriatic Arthritis - Discontinued Products 224

Psoriatic Arthritis - Product Development Milestones 225

Featured News & Press Releases 225

Appendix 239

Methodology 239

Coverage 239

Secondary Research 239

Primary Research 239

Expert Panel Validation 239

Contact Us 239

Disclaimer 240

List of Tables

List of Tables

Number of Products under Development for Psoriatic Arthritis, H2 2017 13

Number of Products under Development by Companies, H2 2017 15

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 16

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 17

Products under Development by Companies, H2 2017 18

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 19

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 20

Products under Development by Companies, H2 2017 (Contd..3), H2 2017 21

Number of Products by Stage and Target, H2 2017 23

Number of Products by Stage and Mechanism of Action, H2 2017 25

Number of Products by Stage and Route of Administration, H2 2017 27

Number of Products by Stage and Molecule Type, H2 2017 29

Psoriatic Arthritis – Pipeline by 3SBio Inc, H2 2017 30

Psoriatic Arthritis – Pipeline by AbbVie Inc, H2 2017 31

Psoriatic Arthritis – Pipeline by AbGenomics International Inc, H2 2017 31

Psoriatic Arthritis – Pipeline by Aclaris Therapeutics Inc, H2 2017 31

Psoriatic Arthritis – Pipeline by Adello Biologics LLC, H2 2017 32

Psoriatic Arthritis – Pipeline by Allergan Plc, H2 2017 32

Psoriatic Arthritis – Pipeline by Alteogen Inc, H2 2017 33

Psoriatic Arthritis – Pipeline by Amgen Inc, H2 2017 33

Psoriatic Arthritis – Pipeline by Biocon Ltd, H2 2017 34

Psoriatic Arthritis – Pipeline by Bionovis SA, H2 2017 34

Psoriatic Arthritis – Pipeline by Coherus BioSciences Inc, H2 2017 34

Psoriatic Arthritis – Pipeline by Eli Lilly and Co, H2 2017 35

Psoriatic Arthritis – Pipeline by Formycon AG, H2 2017 35

Psoriatic Arthritis – Pipeline by Forward Pharma AS, H2 2017 36

Psoriatic Arthritis – Pipeline by Fresenius SE & Co KGaA, H2 2017 36

Psoriatic Arthritis – Pipeline by Galapagos NV, H2 2017 37

Psoriatic Arthritis – Pipeline by Genor BioPharma Co Ltd, H2 2017 37

Psoriatic Arthritis – Pipeline by Immunwork Inc, H2 2017 38

Psoriatic Arthritis – Pipeline by Innovent Biologics Inc, H2 2017 38

Psoriatic Arthritis – Pipeline by Johnson & Johnson, H2 2017 38

Psoriatic Arthritis – Pipeline by KPI Therapeutics Inc, H2 2017 39

Psoriatic Arthritis – Pipeline by Morphotek Inc, H2 2017 39

Psoriatic Arthritis – Pipeline by Mycenax Biotech Inc, H2 2017 40

Psoriatic Arthritis – Pipeline by Nichi-Iko Pharmaceutical Co Ltd, H2 2017 40

Psoriatic Arthritis – Pipeline by Novo Nordisk AS, H2 2017 41

Psoriatic Arthritis – Pipeline by Nuevolution AB, H2 2017 41

Psoriatic Arthritis – Pipeline by Oncobiologics Inc, H2 2017 42

Psoriatic Arthritis – Pipeline by Pfizer Inc, H2 2017 42

Psoriatic Arthritis – Pipeline by Reliance Life Sciences Pvt Ltd, H2 2017 43

Psoriatic Arthritis – Pipeline by Rigel Pharmaceuticals Inc, H2 2017 43

Psoriatic Arthritis – Pipeline by Sandoz International GmbH, H2 2017 44

Psoriatic Arthritis – Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017 44

Psoriatic Arthritis – Pipeline by SynAct Pharma AB, H2 2017 44

Psoriatic Arthritis – Pipeline by UCB SA, H2 2017 45

Psoriatic Arthritis – Pipeline by Xbrane Biopharma AB, H2 2017 45

Psoriatic Arthritis – Dormant Projects, H2 2017 226

Psoriatic Arthritis – Dormant Projects, H2 2017 (Contd..1), H2 2017 227

Psoriatic Arthritis – Discontinued Products, H2 2017 228

List of Figures

List of Figures

Number of Products under Development for Psoriatic Arthritis, H2 2017 13

Number of Products under Development by Companies, H2 2017 14

Number of Products by Top 10 Targets, H2 2017 22

Number of Products by Stage and Top 10 Targets, H2 2017 22

Number of Products by Top 10 Mechanism of Actions, H2 2017 24

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 24

Number of Products by Routes of Administration, H2 2017 26

Number of Products by Stage and Routes of Administration, H2 2017 26

Number of Products by Molecule Types, H2 2017 28

Number of Products by Stage and Molecule Types, H2 2017 28

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports